Decreased opioid medication use by 21 percent compared to other minimally-invasive spine surgical techniques
NEW YORK, Sept. 20, 2024 /PRNewswire/ — An emerging type of minimally-invasive spine...
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona,...
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all...
Incyte (Nasdaq: INCY) has announced that its Phase III POD1UM-303/InterAACT2 trial met its primary endpoint of progression-free survival (PFS).The study is testing the...
Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food and Drug Administration (FDA) for multiple cancer types.
The...